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Introduction
Diabetes mellitus is growing global pandemic [1], causing micro- 
and macrovascular complications [2]. Compared with type 1 diabetes 
due to an absolute deficiency of insulin secretion, type 2 diabetes, a much 
more prevalent category, is due to combination of resistance to insulin 
action and an inadequate compensatory insulin secretory response 
[3]. Metformin is the preferred initial pharmacological agent for type 
2 diabetes, and if metformin monotherapy at maximal tolerated dose 
does not achieve or maintain the hemoglobin A1c (HbA1c) target over 
3–6 months, a second agent is needed to control glycemia. Among the 
option of add-on therapy is dipeptidyl peptidase-4 (DPP4) inhibitor 
[4,5]. DPP4 inhibitors have few side effects, and their prescriptions 
have been increasing [6]. 
Oral glucose intake induces glucagon-like peptide-1 (GLP-1) 
and gastric inhibitory polypeptide (GIP), which are insulinotropic 
depending on glucose level. DPP4 deactivates bioactive peptides, 
including GLP-1 and GIP. DPP4 inhibitors bind to this DPP4 and 
control glycemic surge after meal by enhancing the action of GLP-1 
and GIP, consequently [7]. Therefore, the efficacy of DPP4 inhibitors 
might be affected if the expression level of DPP4 is changed or if the 
altered structure of DPP4 affects the affinity with DPP4 inhibitors. 
However, there has been no study which analyzed the association 
between DPP4 polymorphism with the efficacy of DPP4 inhibitors 
discovered so far. Given these points, we discovered DPP4 single 
nucleotide polymorphisms (SNPs) in Korean population and searched 
for polymorphisms that affect the efficacy of vildagliptin, a member of 
DPP4 inhibitor group.
Materials and Methods
Subjects
A total of 48 patients with type 2 diabetes mellitus were recruited 
from the outpatient clinics at Yonsei University Severance Hospital 
Diabetes Center, Seoul, Korea. For this study, type 2 diabetes mellitus 
was defined according to the American Diabetes Association criteria 
[3]. Patients who had received metformin monotherapy and whose 
HbA1c values ranged from 6% to 8% were enrolled. All patients 
were treated with vildagliptin for at least 12 weeks as add-on therapy 
following metformin monotherapy. All enrolled patients took 50 mg 
vildagliptin daily (as a q.d. dose) or 100 mg vildagliptin daily (as equally 
divided doses). The inclusion criteria were as follows: (1) age 20 to 90 
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Abstract
Background: The dipeptidyl peptidase-4 (DPP4) inhibitors have become widely used antidiabetic medication. 
They control glycemia by interacting with serum DPP4 to interfere catalyzation of incretins. The aim of this pilot study 
was to discover the DPP4 polymorphisms that could affect the efficacy of vildagliptin, a DPP-4 inhibitor in diabetic 
patients.
Methods: Genetic variations in DPP4 were identified in 48 patients with type 2 diabetes who received vildagliptin 
treatment at least 12 weeks following metformin monotherapy. Luciferase assay was performed to estimate the 
effect of the regulatory single nucleotide polymorphism (SNP) on expression of DPP4.
Results: Eight tagging SNPs were genotyped in a sample of 24 patients. Additional sample of 24 patients was 
used to discover further regulatory SNPs and coding SNPs. In all 48 patients, responders (degree of HbA1c and/or 
fasting glucose level decrease greater than 10% of baseline after 12 weeks of vildagliptin add-on treatment) did not 
show any significant difference in selected six DPP4 polymorphisms from non-responders. DPP4 expression was 
not different according to g.-234A/C in luciferase assay.
Conclusion: Our pilot study could not find any significant genetic variant which is associated with vildagliptin 
response in patients with type 2 diabetes. Further studies in large population are warranted.
Discovery of DiPeptidyl Peptidase-4 Gene Variants and the 
Associations with Efficacy of Vildagliptin in Patients with Type 2 
Diabetes - A Pilot Study
Obin Kwon1,2, Eun Yeong Choe3, Younjeong Choi3, Hyun Min Kim3, Hye Jin Wang2,4, Hyangkyu Lee5, Chul Hoon Kim1,2 and Eun Seok Kang2-4*
1Department of Pharmacology, Yonsei University College of Medicine, Korea
2Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Korea
3Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Korea
4Institute of Endocrine Research, Yonsei University College of Medicine, Korea 
5Department of Clinical Nursing Science, Yonsei University College of Nursing, Korea 
Citation: Kwon O, Choe EY, Choi Y, Kim HM, Wang HJ, et al. (2013) Discovery of DiPeptidyl Peptidase-4 Gene Variants and the Associations with 
Efficacy of Vildagliptin in Patients with Type 2 Diabetes - A Pilot Study. J Diabetes Metab S13: 006. doi:10.4172/2155-6156.S13-006
Page 2 of 6
 J Diabetes Metab        Type 2 Diabetes Mellitus- Disease, Diagnosis & Treatment            ISSN: 2155-6156 JDM, an open access journal
years, (2) no previous history of DPP4 inhibitor use, (3) no medication 
change in the last 3 months, and (4) for women, postmenopause or use 
of appropriate contraceptive methods. Patients with type 1 diabetes, 
a history of ketoacidosis, ischemic heart disease, or congestive heart 
failure (New York Heart Association class II-IV), and pregnant 
or lactating women were excluded from this study. Response to 
vildagliptin add-on treatment was defined by modification of criteria 
suggested by Blüher et al. [8]. Responders were defined as a greater than 
10% decrease in HbA1c values or fasting plasma glucose (FPG) levels 
(or both) after 12 weeks of vildagliptin treatment. Non-responders 
were defined as those patients who did not meet these criteria. This 
pilot study protocol was approved by the Institutional Review Board 
of Yonsei University College of Medicine, Seoul, Korea (4-2011-0912), 
and all subjects provided written informed consent.
Study assessments
FPG, 2-hour postprandial plasma glucose (PPG), and HbA1c were 
assessed initially and during two additional visits, at weeks 12 and 24 of 
treatment. Body mass index (BMI), standard biochemistry laboratory 
profile and fasting plasma insulin level before initial administration 
of vildagliptin were collected. Initial homeostatic model assessment 
of insulin resistance (HOMA-IR) and homeostatic model assessment 
of beta-cell function (HOMA-B) were calculated. Genomic DNA was 
isolated from peripheral blood lymphocytes. 
Gene scanning
Gene scanning was performed to discover DPP4 polymorphisms 
prevalent in the Korean diabetes population. For initial discovery, 
24 diabetic patients were recruited. A promoter region -2.6 kb from 
the translation initiation site, the entire coding exons, and flanking 
intronic sequences of the DPP4 gene were amplified in 28 polymerase 
chain reaction (PCR) fragments and sequenced by an automated 
genetic analyzer (Model 3730xl,Applied Biosystems, Foster City, CA). 
Haplotype analysis was performed using the Haploview 4.1 program 
based on a standard expectation-maximization algorithm to construct 
haplotype blocks. For further discovery of regulatory SNPs (rSNPs) and 
coding SNPs (cSNPs), 24 additional diabetic patients were recruited. 
DPP4 gene was amplified in 9 PCR fragments and sequenced targeting 
rSNPs and 17 non-synonymous SNPs (nsSNPs) that were predicted 
as possible impact on the structure and function of DPP4 protein by 
Polyphen-2 [9] and/or SIFT [10].
Measurements of DPP4 promoter activity in vitro
To construct the reporter plasmids containing human DPP4 
promoter region, a 477-bp fragment of human DPP4 (-507 to -31relative 
to the translation initiation site) was amplified with DNA samples 
from homozygotes with DPP4 g.-234C or g.-234A. Manufacture of this 
fragment was modified from the construct which had showed the most 
luciferase activity in previous study by Böhm et al.[11]. The amplified 
products were inserted into pGL3-basicluciferase reporter vectors 
(Promega Corporation, Madison, WI) using restriction enzyme sites 
and DNA sequences were confirmed by dideoxynucleotide-based 
sequencing. 
Caco-2 cells originated from human colorectal adenocarcinoma 
were cultured in Dulbecco’s modified Eagle’s medium formulated 
with 4500 mg/L glucose, supplemented with 20% fetal bovine serum, 
100 U/mL penicillin G, and 100 mg/mL streptomycin. ThepGL3-
basicplasmidscontaining DPP4 promoters and control Renilla luciferase 
vectors were co-transfected into Caco-2 cells using jetPRIME (Polyplus 
transfection, Illkirch, France). Luciferase assays were performed using 
Dual-Luciferase Reporter Assay System (Promega) according to the 
manufacturer’s instructions. Light emission was measured using a 
microplate luminometer (Berthold Technologies, Wildbad, Germany).
In silico identification of putative transcription factor binding 
sites in DPP4 promoter sequences
To identify putative transcription factor binding site in DPP4 
promoter sequences, the DPP4 sequences around g.-234 site were 
analyzed using two different transcription factor binding site prediction 
programs, PROMO 3.0.2 [12] and MatInspector from Genomatix 
Software Suite [13].
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics 
20 (IBM Corp. Armonk, NY) and Graphpad Prism 5.0 (Graphpad 
Software, Inc., San Diego, CA) software packages. Differences between 
responder and non-responder groups were tested by use of chi-square 
tests or t-tests for categorical and continuous variables, respectively. 
Genotype/allele frequency comparisons between responder and non-
responder groups were performed by chi-square tests. Fisher’s exact 
test was used if expected cell frequencies were lower than 5. Multivariate 
logistic regression was performed to evaluate the major determinants 
of vildagliptin response. Genotype frequencies at each SNP were tested 
for Hardy-Weinberg equilibrium. All P values were based on two-sided 
comparisons and P values less than 0.05 were considered statistically 
significant.
Results
The baseline characteristics of the 35 responder and 13 non-
responder subjects are presented in Table 1. There were no statistical 
differences in baseline characteristics between the two groups, including 
FPG, 2-hour PPG, and HbA1c. After 3 months of add-on therapy, the 
degree of HbA1c and/or FPG level decrease was significantly greater 
in the responder group than in the non-responder group (P<0.001, 
respectively). After 6 months of add-on therapy, HbA1c was still 
maintained significantly lower in responder group (P<0.001).
To discover DPP4 polymorphisms, dideoxynucleotide-based DNA 
sequencing was performed using samples derived from twenty-four 
type 2 diabetic patients. A total of 14 genetic variations were discovered 
after comprehensive gene scanning, covering all exons, exon-intron 
junctions and a promoter region up to 2.6 kb from the translation 
initiation site. No nsSNP was discovered in enrolled patients. The 
linkage-disequilibrium (LD) structure of the DPP4 gene is shown in 
Figure 1. Of the 14 variations, two with an allele frequency less than 5% 
were excluded from further analyses. Finally, eight tagging SNPs were 
selected for DPP4 genotyping as detailed in Materials and Methods.
To discover SNPs affecting the efficacy of vildagliptin, 24 additional 
diabetic patients were recruited. Targeted SNPs were rSNPs within 500 
base pairs from starting codon and 17 nsSNPs predicted as possible 
impact on the structure and function of DPP4 protein. Synonymous 
SNP (sSNP) G645G (rs17848910), rSNPg.-234A/C (rs13015258) and 
other intervening sequences (IVSs) were discovered in this step. No 
nsSNP was discovered. To evaluate whether DPP4 genetic variations 
are associated with glucose-lowering effect of vildagliptin, a case-
control association analysis was performed using genotype data on 
the 6 SNPs, including G645G andg.-234A/C. (Table 2). The genotype 
distributions of all SNPs were in accordance with Hardy-Weinberg 
equilibrium (P>0.05) in each set of samples. Of the six SNPs tested, 
there was no SNP strongly associated with efficacy of vildagliptin. 
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Multivariate logistic regression analyses were performed to define 
the major determinants for vildagliptin treatment response and to 
reveal other parameters influencing the response rate. No SNPs were 
found to be a major determinant of response rate (Table 3). Multiple 
logistic regression analyses revealed that baseline HbA1c was the major 
confounding factor of therapeutic response to vildagliptin.
To measure the promoter activity of DPP4 according to rSNP g.-
234A/C, reporter constructs containing the rSNP were constructed 
and their transcriptional activities were measured in Caco-2 cells. The 
transcriptional activities of major allele and minor C allele showed no 
significant difference (Figure 2).
Discussion
In this study, we examined the effects of the polymorphisms of 
the DPP4 gene on the response to vildagliptin in Korean patients with 
type 2 diabetes mellitus. The results of this pilot study do not support 
the notion that DPP4 polymorphisms modulate the efficacy of DPP4 
inhibitors among diabetic patients. In the first screening of DPP4 
polymorphisms from 24 diabetic patients, we failed to discover nsSNPs 
that may possibly impact the structure and function of DPP4 protein 
in Korean population. There was no nsSNP found in the second set 
of samples from other 24 diabetic patients, either. Only sSNP G645G 
showed a modest P value of 0.175 in multivariate logistic regression 
of response to vildagliptin add-on therapy, which leaves room for 
possibility of association with increased number of subjects enrolled. 
Instead, the multiple logistic regression tests revealed that baseline 
HbA1c was the major confounding factor of therapeutic response to 
vildagliptin add-on: in other words, the efficacy of vildagliptin add-on 
is less to relatively well-controlled diabetic patients.
Regulatory SNP g.-234A/C discovered in this study did not 
influence the efficacy of vildagliptin in clinical data and in vitro study. 
To identify potential transcriptional elements that might be involved 
in regulating the transcriptional activity of DPP4 in silico, sequences 
around g.-234A/C were analyzed using two different transcription 
Characteristic Responder Non-responder P value
No. of subjects 35 (72.9) 13 (27.1)
Male 15 (42.9) 6 (46.2) 0.838
Age (year) 60.4 (12.4) 57.4 (10.1) 0.441
Body mass index (kg/m2) 25.01 (3.72) 26.24 (3.56) 0.344
Duration of diabetes (year) 7.54 (5.17) 8.85 (4.96) 0.437
Baseline
   FPG (mmol/L) 6.79 (1.05) 6.80 (0.79) 0.980
   2-hour PPG (mmol/L) 10.73 (2.84) 11.03 (2.04) 0.737
   HbA1c (%) 7.25 (0.40) 7.00 (0.42) 0.059
   Fasting plasma insulin (pmol/L) 90.42 (79.03) 48.27 (17.15) 0.214
   Blood urea nitrogen (mmol/L) 5.22 (1.25) 4.97 (1.66) 0.568
   Creatinine (μmol/L) 72.49 (13.26) 81.33 (15.91) 0.065
   eGFR (mL/min/1.73m2) 89.94 (15.27) 82.50 (15.93) 0.156
   Aspartate aminotransferase (IU/L) 20.34 (10.87) 22.62 (7.47) 0.492
   Alanine aminotransferase (IU/L) 24.00 (18.69) 24.85 (12.32) 0.881
   Total cholesterol (mmol/L) 4.47 (0.76) 4.51 (0.89) 0.902
   HDL cholesterol (mmol/L) 1.23 (0.27) 1.21 (0.26) 0.819
   LDL cholesterol (mmol/L) 2.59 (0.68) 2.51 (0.82) 0.759
   Triglyceride (mmol/L) 1.41 (0.59) 1.78 (0.50) 0.056
   HOMA-B 105.52 (141.48) 46.77 (23.61) 0.329
   HOMA-IR 3.60 (2.70) 2.06 (0.66) 0.185
   Dose of daily metformin (mg) 945.71 (392.65) 976.92 (454.89) 0.816
   Dose of daily vildagliptin (mg) 87.14 (22.17) 84.62 (24.02) 0.733
3 month after Vildagliptin administration
   FPG (mmol/L) 6.06 (1.00) 7.42 (1.29) <0.001
   ΔFPG (mmol/L) -0.73 (0.92) 0.62 (1.13) <0.001
   2-hour PPG (mmol/L) 8.34 (2.28) 10.08 (2.81) 0.035
   Δ2-hour PPG (mmol/L) -2.43 (2.89) -1.40 (1.40) 0.117
   HbA1c (%) 6.26 (0.44) 6.87 (0.59) <0.001
   ΔHbA1c (%) -0.99 (0.32) -0.13 (0.51) <0.001
6 month after Vildagliptin administration
   FPG (mmol/L) 6.24 (1.00) 6.89 (1.29) 0.098
   ΔFPG (mmol/L) -0.59 (0.90) 0.10 (0.81) 0.024
   2-hour PPG (mmol/L) 8.66 (2.28) 10.63 (2.81) 0.024
   Δ2-hour PPG (mmol/L) -2.07 (2.65) -0.39 (2.71) 0.074
   HbA1c (%) 6.28 (0.32) 6.80 (0.68) 0.003
   ΔHbA1c (%) -0.97 (0.42) -0.20 (0.41) <0.001
Results expressed as n (%) or mean values (SD). Chi-square test or t-test was used for P value where appropriate. Δ means the difference from baseline level. Abbreviations: 
FPG: Fasting Plasma Glucose; PPG: Postprandial Plasma Glucose; eGFR: Estimated Glomerular Filtration Rate; HDL: High Density Lipoprotein; LDL: Low Density 
Lipoprotein; HOMA-B: Homeostatic Model Assessment of Beta Cell Function; HOMA-IR: Homeostatic Model Assessment of Insulin Resistance
Table 1: Characteristics of the 48subjects according to response to vildagliptin add-on therapy.
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factor binding site prediction programs (Supplement File).The results 
showed some different putative transcriptional elements between 
genotypes for dissimilarity percentage and random expectation (RE; 
the lower dissimilarity and/or RE value, the more reliable the hit), 
which might be false positive (Table 1) [14]. Other methods including 
electrophoretic mobility shift assay (EMSA) and correlation with DPP4 
concentration in blood sample can help to discriminate potential 
binding of transcriptional elements.
DPP4 is the key enzyme responsible for cleaving and inactivating 
both GLP-1 and GIP at the penultimate alanine residue [15]. To inhibit 
this inactivation, two drug classes based on their structure have been 
developed as DPP4 inhibitors: peptidomimetics that mimic the DPP4 
molecule (ex. vildagliptin and saxagliptin) and non-peptidomimetics 
(ex. sitagliptin and linagliptin). When peptidomimetics bind to DPP4, 
they dissociate slowly resulting in persistent inhibition of DPP4 
even after inactivation, although they are cleared from the plasma 
relatively quickly. In contrast, non-peptidomimetics form non-
covalent interactions with residues in the catalytic site, which result in 
immediate and potent inhibition [16]. In these contexts, DPP4 nsSNPs 
that have impact on the structure and function of DPP4 protein may 
exert greater effect on the efficacy of sitagliptin or linagliptin compared 
to vildagliptin or saxagliptin because of its influence on the binding 
affinity. Moreover, the effect on the expression level of DPP4 protein 
according to DPP4 rSNPs might be different between the two classes of 
DPP4 inhibitors. These points leave room for further pharmacogenetic 
study of DPP4 inhibitors.
Our group has studied pharmacogenetics of glucose-lowering 
drugs, including the effect of polymorphism of adiponectin, 
peroxisome proliferator-activated receptor gamma2 (PPARγ2), and 
lipin 1 genes on the efficacy of rosiglitazone [17-19], and effect of 
Group n (%) Group n (%)
SNP Genotype Responder Non-responder Allele Responder Non-responder P value
g.-234A/C A/A 16 (45.7) 8 (61.5) A 50 (71.4) 20 (76.9) 0.590
  
(rs13015258) A/C 18 (51.4) 4 (30.8) C 20 (28.6) 6 (23.1)
C/C 1 (2.9) 1 (7.7)
IVS8-128A/G G/G 31 (88.6) 11 (84.6) G 66 (94.3) 24 (92.3) 0.661
  
(rs17848920) G/A 4 (11.4) 2 (15.4) A 4 (5.7) 2 (7.7)
IVS8+46C/T C/C 18 (51.4) 5 (38.5) C 51 (72.9) 17 (65.4) 0.474
  
(rs10930040) C/T 15 (42.9) 7 (53.8) T 19 (27.1) 9 (34.6)
T/T 2 (5.7) 1 (7.7)
IVS11-
143A/G* G/G 20 (57.1) 5 (38.5) G 51 (72.9) 17 (65.4) 0.474
  (rs2302873) G/A 11 (31.4) 7 (53.8) A 19 (27.1) 9 (34.6)
A/A 4 (11.4) 1 (7.7)
G645G C/C 25 (73.5) 12 (92.3) C 59 (86.8) 25 (96.2) 0.275
  
(rs17848910) C/T 9 (26.5) 1 (7.7) T 9 (13.1) 1 (3.8)
IVS22+4C/T T/T 31 (91.2) 10 (76.9) T 65 (95.6) 23 (88.5) 0.342
  (rs2268891) T/C 3 (8.8) 3 (23.1) C 3 (4.4) 3 (11.5)
Nucleotide location number of SNP was assigned according to the DPP4 mRNA sequence (GenBank accession number: NM_001935.3). In comparison between alleles, 
P values were obtained by using Chi-square test or Fisher’s exact test (expected cell value < 5). 
Abbreviations: IVS: Intervening Sequence; SNP: Single Nucleotide Polymorphism. * Linkage with rs10930040
Table 2: Frequency of DPP4 genetic variations in diabetic patients according to response to vildagliptin add-on therapy.
OR: Odds Ratio; CI: Confidence Interval
Table 3: Multivariate logistic regression analyses for influence of clinical and biochemical factors on response to vildagliptin treatment.
A. g.-234A/C genotype of DPP4
Variable OR (95% CI) P value
Gender (0=male, 1=female) 0.87 (0.264-2.871) 0.821
Age 0.97 (0.925-1.018) 0.215
Body mass index 1.05 (0.894-1.233) 0.551
Duration of diabetes 1.06 (0.930-1.206) 0.389
HbA1c 0.05 (0.008-0.273) <0.001
g.-234A/C allele (0=A, 1=C) 0.52 (0.145-1.900) 0.326
B. G645G genotype of DPP4
Variable OR (95% CI) P value
Gender (0=male, 1=female) 0.78 (0.223-2.717) 0.694
Age 0.97 (0.927-1.021) 0.267
Body mass index 1.05 (0.887-1.240) 0.575
Duration of diabetes 1.06 (0.928-1.216) 0.382
HbA1c 0.04 (0.007-0.243) <0.001
G645G allele (0=C, 1=T) 0.19 (0.017-2.110) 0.175
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polymorphism of perilipin gene on the side effects of rosiglitazone [20]. 
For the associations between DPP4 polymorphisms and metabolic 
diseases, several studies had been published. Aghili et al. [21] revealed 
that rs3788979 is associated with the risk of myocardial infarction 
in patients with atherosclerosis. Bouchard et al. [22] analyzed the 
association between DPP4 polymorphisms and cardiovascular disease 
risk factors from over a thousand samples in multi-stage study in 2009. 
Although 3 SNPs were associated with hyperglycemia/diabetes or high 
plasma triglyceride levels in the first stage, those associations failed 
to be replicated in stage 2. This study group, however, revealed the 
methylation rate of DPP4 gene DNA of visceral adipose tissue (VAT) 
from severe obesity patients to be different between the genotypes for 
three DPP4 polymorphisms in 2011 [23], including the SNP associated 
with hyperglycemia/diabetes in the first stage of previous study. DPP4 
polymorphisms were also studied for association with diseases other 
than metabolic disorders including periodontitis and major depressive 
disorders [24,25]. Rs 6741949 was shown to be associated with 
reduction in hippocampal volume, which is accelerated by Alzheimer’s 
disease and vascular risk factors [26].
The major limitation of this study is the low number of enrolled 
subjects due to the nature of this research as a pilot study. The discovery 
in this study does not include normal healthy control data, which makes 
impossible to compare DPP4 polymorphisms of diabetic patients with 
that of healthy control. These points leave room for further pharmaco 
genetic study of DPP4 polymorphism in Korean population.
Conclusion
The current study analyzed the genotype of DPP4 gene in Korean 
diabetic populations. Our results do not support the notion that 
DPP4 polymorphisms are related with the glucose-lowering effect of 
vildagliptin. Further investigations with higher number of samples 
and comprehensive analysis are needed to reveal hidden associations 
between DPP4 polymorphisms and efficacy of DPP4 inhibitors/GLP-1 
analogues in diabetic patients.
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Figure 2: Measurements of DPP4 promoter activity according to regulatory 
SNP g.-234A/C. The transcriptional activity of the DPP4 promoter genotype 
of g.-234A/C was analyzed by luciferase-based reporter assay as detailed in 
Materials and Methods. Reporter vectors containing -507 to -31 region of the 
DPP4 gene were cloned from homozygote with each of the genotype. Promoter 
activities were measured in Caco-2 cells (n=3) 2 days after transfection with 
the reporter plasmid. The reporter activity of each construct was compared 
with that of the control mock vector (pGL3-basic). Values are presented as 
means ± SD.
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